127 related articles for article (PubMed ID: 9858214)
21. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
22. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.
Iurescia S; Fioretti D; Pierimarchi P; Signori E; Zonfrillo M; Tonon G; Fazio VM; Rinaldi M
J Biomed Biotechnol; 2010; 2010():316069. PubMed ID: 20445751
[TBL] [Abstract][Full Text] [Related]
23. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
[TBL] [Abstract][Full Text] [Related]
24. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy.
Abe A; Emi N; Taji H; Kasai M; Kohno A; Saito H
Gene Ther; 1996 Nov; 3(11):988-93. PubMed ID: 8940639
[TBL] [Abstract][Full Text] [Related]
25. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity.
Bende RJ; Aarts WM; Riedl RG; de Jong D; Pals ST; van Noesel CJ
J Exp Med; 2005 Apr; 201(8):1229-41. PubMed ID: 15837810
[TBL] [Abstract][Full Text] [Related]
26. Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens.
Thielemans K; Rothbard JB; Levy S; Levy R
J Exp Med; 1985 Jul; 162(1):19-34. PubMed ID: 3925067
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
28. Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
Miyai M; Eikawa S; Hosoi A; Iino T; Matsushita H; Isobe M; Uenaka A; Udono H; Nakajima J; Nakayama E; Kakimi K
PLoS One; 2015; 10(8):e0136086. PubMed ID: 26291626
[TBL] [Abstract][Full Text] [Related]
29. VH gene usage and CDR3 analysis of B cell receptor in the peripheral blood of patients with PBC.
Foreman AL; Lemercier B; Lim A; Kourlisky P; Kenny T; Gershwin ME; Gougeon ML
Autoimmunity; 2008 Feb; 41(1):80-6. PubMed ID: 18176868
[TBL] [Abstract][Full Text] [Related]
30. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
31. Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas.
De Re V; De Vita S; Gasparotto D; Marzotto A; Carbone A; Ferraccioli G; Boiocchi M
Eur J Immunol; 2002 Mar; 32(3):903-10. PubMed ID: 11870635
[TBL] [Abstract][Full Text] [Related]
32. Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells.
Hernández T; de Acosta CM; López-Requena A; Moreno E; Alonso R; Fernández-Marrero Y; Pérez R
Mol Immunol; 2010; 48(1-3):98-108. PubMed ID: 20952071
[TBL] [Abstract][Full Text] [Related]
33. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.
Bergenbrant S; Yi Q; Osterborg A; Björkholm M; Osby E; Mellstedt H; Lefvert AK; Holm G
Br J Haematol; 1996 Mar; 92(4):840-6. PubMed ID: 8616076
[TBL] [Abstract][Full Text] [Related]
34. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
36. Fundamental characteristics of the expressed immunoglobulin VH and VL repertoire in different canine breeds in comparison with those of humans and mice.
Steiniger SC; Dunkle WE; Bammert GF; Wilson TL; Krishnan A; Dunham SA; Ippolito GC; Bainbridge G
Mol Immunol; 2014 May; 59(1):71-8. PubMed ID: 24509215
[TBL] [Abstract][Full Text] [Related]
37. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
Barrios Y; Cabrera R; Yáñez R; Briz M; Plaza A; Forés R; Fernández MN; Díaz-Espada F
Haematologica; 2002 Apr; 87(4):400-7. PubMed ID: 11940484
[TBL] [Abstract][Full Text] [Related]
38. Active idiotypic vaccination in a patient with biclonal follicular lymphoma.
Barrios Y; Plaza A; Cabrera R; Yáñez R; Suárez E; Fernández MN; Díaz-Espada F
Cancer Immunol Immunother; 2001 Apr; 50(2):87-92. PubMed ID: 11401030
[TBL] [Abstract][Full Text] [Related]
39. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma.
Cull G; Durrant L; Stainer C; Haynes A; Russell N
Br J Haematol; 1999 Dec; 107(3):648-55. PubMed ID: 10583271
[TBL] [Abstract][Full Text] [Related]
40. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
